ArticleCurrent oncology (Toronto, Ont.)2024

Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.

Tasuku Nakabori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.